Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan.

about

Palivizumab Prophylaxis Against Respiratory Syncytial Virus Infection in Children with Immunocompromised Conditions or Down Syndrome: A Multicenter, Post-Marketing Surveillance in Japan.

Item

http://www.wikidata.org/entity/Q40046043

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Palivizumab Prophylaxis Agains ...... rketing Surveillance in Japan.

@en

type

Item

label

Palivizumab Prophylaxis Agains ...... rketing Surveillance in Japan.

@en

prefLabel

Palivizumab Prophylaxis Agains ...... rketing Surveillance in Japan.

@en

P1476

Palivizumab Prophylaxis Agains ...... rketing Surveillance in Japan.

@en

P2093

Ken Nomoto

http://www.w3.org/2001/XMLSchema#string

Tomoko Kashiwagi

http://www.w3.org/2001/XMLSchema#string

Yukiko Okada

http://www.w3.org/2001/XMLSchema#string

P2860

Risk of primary infection and reinfection with respiratory syncytial virus.

Randomized, Double-Blind Study of the Pharmacokinetics and Safety of Palivizumab Liquid Formulation Compared with Lyophilized Formulation.

Immunoprophylaxis of respiratory syncytial virus: global experience.

Respiratory syncytial virus: diagnosis, treatment and prevention

Risks and prevention of severe RS virus infection among children with immunodeficiency and Down's syndrome.

Respiratory syncytial virus prophylaxis in Down syndrome: a prospective cohort study.

Palivizumab use in Japanese infants and children with immunocompromised conditions.

A randomized controlled trial of motavizumab versus palivizumab for the prophylaxis of serious respiratory syncytial virus disease in children with hemodynamically significant congenital heart disease.

Nationwide survey of severe respiratory syncytial virus infection in children who do not meet indications for palivizumab in Japan.

From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.

P2888

s40272-017-0264-y

P304

97-104

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40272-017-0264-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28895096

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

5775975

http://www.w3.org/2001/XMLSchema#string